Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPA | P23025 | 18/20 | 0.85 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | APEX1 | P27695 | 1/20 | 0.61 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.61 |
| ▸ | GALK1 | P51570 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | EP300 | Q09472 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388116 | 0.96 | XPA (0.85) | XPAMEN1APEX1NTSR1GALK1 | |
| SCHEMBL19644204 | 0.92 | XPA (1.00) | XPAMEN1APEX1NTSR1GALK1 | |
| SCHEMBL19644205 | 0.92 | XPA (1.00) | XPAMEN1APEX1NTSR1GALK1 | |
| SCHEMBL19644222 | 0.92 | XPA (1.00) | XPAMEN1APEX1NTSR1GALK1 | |
| SCHEMBL29385646 | 0.92 | XPA (0.72) | XPAMEN1APEX1NTSR1GALK1 | |
| SCHEMBL20840271 | 0.89 | XPA (0.92) | XPAMEN1APEX1NTSR1GALK1 | |
| SCHEMBL19644352 | 0.89 | XPA (0.92) | XPAMEN1APEX1NTSR1GALK1 | |
| SCHEMBL29524675 | 0.89 | XPA (0.75) | XPAMEN1APEX1NTSR1GALK1 | |
| SCHEMBL29388482 | 0.89 | XPA (0.84) | XPAMEN1APEX1NTSR1GALK1 | |
| SCHEMBL19644519 | 0.88 | XPA (1.00) | XPAMEN1APEX1NTSR1GALK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684354-B1 | XPA INHIBITOR COMPOUNDS AND THEIR USE | UNIV INDIANA RES & TECH CORP (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20220089577-A1 | KU INHIBITORS AND THEIR USE | UNIV INDIANA RES & TECH CORP (US) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089577-A1 | KU INHIBITORS AND THEIR USE | ZFR, XRCC6, ZFX | XPA 66/4885MEN1 2172/4885APEX1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.